Compare PLXS & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLXS | SYRE |
|---|---|---|
| Founded | 1979 | 2013 |
| Country | United States | United States |
| Employees | 20000 | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 8.5B |
| IPO Year | 1995 | 2015 |
| Metric | PLXS | SYRE |
|---|---|---|
| Price | $239.19 | $107.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | ★ $206.50 | $85.08 |
| AVG Volume (30 Days) | 292.7K | ★ 794.3K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 56.11 | N/A |
| EPS | ★ 4.90 | N/A |
| Revenue | N/A | ★ N/A |
| Revenue This Year | $14.31 | N/A |
| Revenue Next Year | $8.29 | N/A |
| P/E Ratio | $48.49 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $132.03 | $14.51 |
| 52 Week High | $307.06 | $110.18 |
| Indicator | PLXS | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 40.90 | 60.88 |
| Support Level | $233.67 | $93.45 |
| Resistance Level | $299.61 | N/A |
| Average True Range (ATR) | 10.37 | 4.53 |
| MACD | -2.64 | -0.09 |
| Stochastic Oscillator | 16.71 | 87.74 |
Plexus Corp designs, manufactures, and services complex products in demanding regulatory environments, supporting life-saving medical devices, mission-critical aerospace and defense products, industrial automation systems, and semiconductor capital equipment. Its integrated lifecycle solutions span design and development, supply chain solutions, new product introduction, manufacturing, and sustaining services for market and disruptive companies in the Aerospace/Defense, Healthcare/Life Sciences, and Industrial sectors. The Company operates through three reportable segments: AMER, APAC, and EMEA, with the majority of revenue from the APAC segment.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.